Advanced
Trials portfolio
EACH
Evaluating Avelumab in combination with Cetuximab in Head and neck cancer
The safety run-in will be of a single arm de-escalating design which will recruit up to 16 patients with a variety of recurrent and/or metastatic squamous cell carcinomas. The modified Continual Reass [...]
Area: Head & neck cancer
Phase: Phase II
Status: In follow-up (non-recruiting)
HiLo
Multicentre randomised trial of high dose versus low dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation following surgery for differentiated thyroid cancer.
HiLo was a randomised, phase III factorial randomised trial, stratified according to trial site, T stage and N stage.
Area: Head & neck cancer
Phase: Phase III
Status: In follow-up (non-recruiting)
IoN
Is ablative radiOiodine Necessary for low risk patients.
IoN is a randomised, non-blind, non-inferiority phase III multicentre trial, randomised using the minimisation method and stratified according to site, patient age, T Stage and N Stage to decide if pa [...]
Area: Head & neck cancer
Phase: Phase II/III
Status: Active (recruiting)
ORCA-2
ORCA-2: a phase I study of olaparib in addition to cisplatin based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (NHSCC).
ORCA-2 is a phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck (HNSCC). The [...]
Area: Head & neck cancer
Phase: Phase I
Status: Active (recruiting)
POPPY
A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck.
POPPY is a single-arm phase II trial which aims to evaluate the safety and anti-tumour activity of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell cancer and a perfo [...]
Area: Head & neck cancer
Phase: Phase II
Status: Active (recruiting)
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2019 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us